| May 12 |
TEVA
|
These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio? |
| May 10 |
CANF
|
Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV |
| May 10 |
CANF
|
Can-Fite receives FDA IND clearance for Phase IIb MASH treatment trial |
| May 9 |
TEVA
|
TEVA Q1 Earnings Miss, Schizophrenia Study Meets Goal, Stock Up |
| May 9 |
CYBR
|
CyberArk Previews IMPACT 24: The Identity Security Conference |
| May 9 |
TEVA
|
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2024 Earnings Call Transcript |
| May 9 |
TEVA
|
Affirm stock sinking, Good Buy or Goodbye: Market Domination |
| May 9 |
CANF
|
Can-Fite stock up on FDA IND clearance for namodenoson to treat MASH patients in mid-stage study |
| May 9 |
TEVA
|
Teva Pharmaceutical Industries First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags |
| May 9 |
TEVA
|
Teva Pharmaceutical: 6 Takeaways From Q1 2024 Earnings Results |
| May 9 |
CANF
|
Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study |
| May 9 |
TEVA
|
Teva and Medincell report positive data for TEV-‘749 in schizophrenia trial |
| May 9 |
TEVA
|
Teva: Sustained Revenue Growth Amid Financial Strain (Rating Downgrade) |
| May 8 |
TEVA
|
Teva Pharmaceutical Industries (TEVA) Q1 2024 Earnings Call Transcript |
| May 8 |
TEVA
|
Teva Pharmaceutical Industries Limited (TEVA) Q1 2024 Earnings Call Transcript |
| May 8 |
TEVA
|
Teva hits a five-year high on schizophrenia trial win, Q1 beat |
| May 8 |
TEVA
|
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates |
| May 8 |
TEVA
|
Teva Surges To 5-Year High On Maintained Outlook Despite Mixed First Quarter |
| May 8 |
TEVA
|
Teva Pharmaceutical Industries Limited 2024 Q1 - Results - Earnings Call Presentation |
| May 8 |
TEVA
|
UPDATE 1-Teva Pharm Q1 profit misses estimates, revenue risea |
